Endocyte Inc. buy DomRuinart
Summary
This prediction ended on 07.04.15 with a price of €5.49. The prediction had a final performance of 18.81%. DomRuinart has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Endocyte Inc. | - | - | - | - |
iShares Core DAX® | 1.665% | 0.362% | 17.556% | 15.301% |
iShares Nasdaq 100 | -0.475% | -3.195% | 26.812% | 36.536% |
iShares Nikkei 225® | 2.620% | 1.174% | 17.273% | 10.880% |
iShares S&P 500 | -0.091% | -1.597% | 24.739% | 36.919% |
Comments by DomRuinart for this prediction
In the thread Endocyte Inc. diskutieren
Einstiegschance
Ich denke audf dem Niveau kann man hier mal einsteigen. Der TARGET Trial mit Vynfinit hat die Erwartungen erfüllt. Im 2. Halbjahr stehen noch vielversprecgende Phase 1 updates mit Tubulysin an. Weitere Krebsmedikamente in der Pipeline und noch über 200 Mio $ in cash sollten den Kurs jetzt ein solides Fundament geben:
Endocyte, Inc. (NASDAQ:ECYT) announced an encouraging interim update on overall survival (OS) of patients in a phase IIb study (TARGET) evaluating vintafolide (a small molecule drug conjugate, or SMDC) in combination with Taxotere for the treatment of folate receptor (FR) positive recurrent non-small cell lung cancer (NSCLC). The company is evaluating vintafolide as a second line treatment for patients suffering from NSCLC who have failed one prior line of therapy. On last trading day Endocyte, Inc. (NASDAQ:ECYT) advanced 4.01% to close at $5.97. ECYT is -82.28% away from its 52 week high and is moving 7.57% ahead of its 52 week low. Endocyte, Inc. (NASDAQ:ECYT) return on investment (ROI) is -20.70% while return on equity (ROE) is 11.20%.
Quelle: Wallstreet Scope